CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-10-26): Low glycated hemoglobin linked with liver disease

Epidemiology

Low glycated hemoglobin linked with liver disease

Last Updated: 2011-10-26 15:00:26 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Low levels of glycated hemoglobin (HbA1c) may be associated with certain markers of liver dysfunction, a new study shows.

"Low HbA1c may be a general marker of poor health, analogous to low cholesterol levels," the researchers say -- although the lead author of the study told Reuters Health it's too soon to say everyone with a low HbA1c level should be screened for liver disease.

In a population-based study the research team found J-shaped associations between HbA1c and elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and hepatic steatosis.

Compared with HbA1c levels between 5.0% and 5.5%, a level below 4.0% was linked with a 3.62-fold increased risk of ALT elevations and a 6.8-fold increased risk for AST elevations, according to a report in the September 27th online issue of Diabetes Care.

Levels below 4% were also associated with higher risks for abnormal gamma glutamyltransferase (GGT) and hepatic steatosis, but these associations were not statistically significant.

After excluding patients with anemia, iron overload, or hepatitis B or C, the associations were no longer significant.

Similarly, HbA1c below the 1st percentile was associated with significantly increased risks for high ALT (3.18-fold) and AST (5.80-fold), but not for elevated GGT or hepatic steatosis.

"With the new recommendations by the American Diabetes Association and World Health Organization for the use of HbA1c for the screening and diagnosis of diabetes, physicians may encounter low HbA1c values more often than before," said lead author Andrea L. Christman from Johns Hopkins University, Baltimore, Maryland in an email to Reuters Health.

"Our study suggests that low HbA1c test results may reflect other underlying health conditions, possibly liver disease," she said.

Her group's conclusions are drawn from data on 12,533 participants in the Third National Health and Nutrition Examination Survey (NHANES III 1988-1994) without self-reported diabetes.

"We did not observe an association between low fasting glucose and liver disease," the researchers note, "suggesting that the association with low HbA1c may be independent of glycemic pathways."

"It is premature to recommend routine screening for liver disease in the setting of low HbA1c," Christman said. "Additional studies to understand health implications of very low HbA1c are warranted. In particular, including HbA1c testing in studies of liver disease will be important."

"Physicians should be aware that conditions exist (e.g., anemia, iron overload) that may interfere with HbA1c interpretation," Christman added. "Using repeat testing by different methods and/or testing fasting glucose can be helpful to rule out laboratory error and many interfering conditions."

SOURCE: http://bit.ly/vK7Ui2

Diabetes Care 2011.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.